文献速递神经肿瘤脊柱脊髓外科

儿童脊髓低级别胶质瘤疾病进展高发:德国LGG研究组的管理策略与结果

High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group.
PubMed 文献 · Neuro Oncol · 2021-01-01

该研究分析了128例儿童脊髓低级别胶质瘤患者的临床数据,来自HIT-LGG 1996、SIOP-LGG 2004及LGG-Interim登记研究。10年总生存率为93%±2%,无事件生存率为38%±5%。多数患者出现疾病进展,超过三分之一需要多次干预,但多模式治疗可实现长期疾病控制。

要点

  • 儿童脊髓LGG以毛细胞星形细胞瘤为主(76%),KIAA1549-BRAF融合占40%。
  • 10年OS为93%±2%,EFS为38%±5%,播散性疾病与较差生存相关。
  • 73/128例患者出现一次或多次进展,多模式治疗可实现长期控制。

核心结论

  • 多数儿童脊髓LGG患者会出现疾病进展,甚至发生在多年后。
  • 超过三分之一的患者需要多次干预,但多模式治疗可实现长期疾病控制。
  • 分子检测可能揭示治疗靶点。

研究设计与样本

  • 分析128例儿童脊髓LGG患者的临床数据集,来自前瞻性多中心试验HIT-LGG 1996(n=36)、SIOP-LGG 2004(n=56)及后续LGG-Interim登记研究(n=36)。

主要发现

  • 脊髓LGG以毛细胞星形细胞瘤为主(76%),KIAA1549-BRAF融合在14/35例(40%)中检出,FGFR1-TACC1融合在3/26例(12%)中检出,BRAFV600E突变在2/66例(3%)中检出。
  • 10年总生存率(OS)为93%±2%,无事件生存率(EFS)为38%±5%。
  • 播散性疾病(n=16)与较差的OS和EFS相关,年龄≥11岁和全切除是EFS的有利因素。
  • 在诊断/初始干预后长达20.8年,73/128例患者经历一次(n=43)或最多六次(n=30)影像学/临床疾病进展。
  • 36例患者重复接受肿瘤切除(范围2-6次),47例需要非手术治疗(化疗n=20;放疗n=10;多线治疗n=17)。

关键数值与推荐

  • 全切除(n=24)或次全/部分切除(n=74)、活检(n=16)或仅影像学诊断(n=3)后观察117例患者。
  • 11例患者首先接受化疗(n=9)或放疗(n=2)。
  • 一次(n=57)或重复(n=16)切除后,73/77例患者实现中位6.5年(范围0.02-20)的长期疾病控制。
  • 非手术治疗后,35/47例患者实现长期疾病控制。

临床怎么用

  • 对儿童脊髓LGG应认识到疾病进展的高风险,即使多年后仍可能发生。
  • 多模式治疗(重复切除、化疗、放疗)可用于实现长期疾病控制。
  • 分子检测(如KIAA1549-BRAF融合、BRAFV600E突变)可能有助于识别治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knowledge on management of pediatric spinal cord low-grade glioma (LGG) is scarce. METHODS: We analyzed clinical datasets of 128 pediatric patients with spinal LGG followed within the prospective multicenter trials HIT-LGG 1996 (n = 36), SIOP-LGG 2004 (n = 56), and the subsequent LGG-Interim registry (n = 36). RESULTS: Spinal LGG, predominantly pilocytic astrocytomas (76%), harbored KIAA1549-BRAF fusion in 14/35 patients (40%) and FGFR1-TACC1 fusion in 3/26 patients (12%), as well as BRAFV600E mutation in 2/66 patients (3%). 10-year overall survival (OS) and event-free survival (EFS) was 93% ± 2% and 38% ± 5%, respectively. Disseminated disease (n = 16) was associated with inferior OS and EFS, while age ≥11 years and total resection were favorable factors for EFS. We observed 117 patients following total (n = 24) or subtotal/partial resection (n = 74), biopsy (n = 16), or radiologic diagnosis only (n = 3). Eleven patients were treated first with chemotherapy (n = 9) or irradiation (n = 2). Up to 20.8 years after diagnosis/initial intervention, 73/128 patients experienced one (n = 43) or up to six (n = 30) radiological/clinical disease progressions. Tumor resections were repeated in 36 patients (range, 2-6) and 47 patients required nonsurgical treatment (chemotherapy, n = 20; radiotherapy, n = 10; multiple treatment lines, n = 17). Long-term disease control for a median of 6.5 (range, 0.02-20) years was achieved in 73/77 patients following one (n = 57) or repeated (n = 16) resections, and in 35/47 patients after nonsurgical treatment. CONCLUSIONS: The majority of patients experienced disease progression, even after years. Multiple interventions were required for more than a third, yet multimodal treatment enabled long-term disease control. Molecular testing may reveal therapeutic targets.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Perwein T, Benesch M, Kandels D, et al. High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. Neuro Oncol. 2021. PMID: 33346834. doi:10.1093/neuonc/noaa296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。